4results about How to "Reduce weight gain" patented technology

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

The invention discloses application of surfactin family lipopeptide in preparation of a medicine for preventing and / or treating non-alcoholic fatty liver disease, and belongs to the field of biological medicine. Experiments prove that the surfactin family lipopeptide can significantly reduce weight gain and liver weight of a model mouse, reduce the ratio of liver weight to weight, relieve HFD-induced hepatic distension and lipid droplet accumulation, improve hepatic lesion, and reduce the liver weight of the model mouse. In addition, according to verification of the invention, single surfactin A, surfactin B or surfactin C can also play a role in improving NAFLD (non-alcoholic fatty liver disease) of mice induced by high fat diet. The significant effect and transformation potential of the surfactin family lipopeptide in prevention and treatment of the non-alcoholic fatty liver are verified, so that the surfactin family lipopeptide can be applied to preparation of drugs for prevention and treatment of the non-alcoholic fatty liver, and a new thought is provided for clinical treatment of prevention and treatment of the non-alcoholic fatty liver.

The invention discloses application of iturin family lipopeptide in preparation of a medicine for preventing and / or treating non-alcoholic fatty liver disease, and belongs to the field of biological medicine. Experiments prove that the iturin family lipopeptide can remarkably reduce weight gain and liver weight of an experimental model mouse, reduce the liver-weight ratio of the mouse, relieve HFD-induced hepatic distension and lipid droplet accumulation and improve hepatic lesion, and the effect of the iturin family lipopeptide is superior to that of a conventional liver protection drug silybin; in addition, according to verification of the invention, it is found that single iturin A or iturin B lipopeptide can also play a role in improving NAFLD of mice induced by high fat diet. The invention verifies the obvious effect and transformation potential of the iturin family lipopeptide in preventing and treating the non-alcoholic fatty liver disease, so that the iturin family lipopeptide can be applied to preparation of the medicine for preventing and treating the non-alcoholic fatty liver disease, and a new thought is provided for clinical treatment of preventing and treating the non-alcoholic fatty liver disease.

The invention discloses application of PQBP1 protein and a gene thereof in drugs for preventing or treating obesity and non-alcoholic fatty liver disease. The invention discloses a shRNA (short hairpin ribonucleic acid) molecule, a recombinant adenovirus vector and an application of the shRNA molecule and the recombinant adenovirus vector in a medicine for preventing or treating obesity or non-alcoholic fatty liver disease. The invention proves that the deficiency of PQBP1 in adipose tissues under normal diet conditions can cause the down-regulation of lipid synthesis related enzyme expression, which shows adipogenesis disorder. The deficiency of PQBP1 in adipose tissue under a high fat diet condition resists the obesity process and improves glucose resistance and the fatty degeneration level of non-alcoholic fatty liver. In addition, the further development of obesity can be slowed down by reducing the expression of the PQBP1 in adipose tissues during early obesity, and related metabolic defects caused by obesity are improved. Therefore, related reagents inhibiting the PQBP1 can provide a new treatment strategy for obesity and related metabolic complications.